Ability Biologics dedicated to developing the most potent and selective antibody therapeutics for areas of great unmet need..
Ability biologics has raised $18.0M in total funding. The most recent round was Seed. The last funding was announced in June 2024.
Ability biologics's investors include Fonds de solidarité FTQ, Charles River Laboratories International, Alexandria Venture Investments, Investissement Quebec, Amplitude Venture Capital.
Ability biologics is headquartered in Ville-marie, Canada.
Ability Biologics dedicated to developing the most potent and selective antibody therapeutics for areas of great unmet need..
Ability biologics is at the Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Ability biologics — Funding & Investors." VCBacked, June 18, 2024, https://www.vcbacked.co/company/ability-biologics. Accessed August 6, 2026.
VCBacked. (2024). Ability biologics — Funding & Investors. Retrieved August 6, 2026, from https://www.vcbacked.co/company/ability-biologics
{{cite web |title=Ability biologics — Funding & Investors |url=https://www.vcbacked.co/company/ability-biologics |website=VCBacked |access-date=August 6, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated